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Abstract
Background: Natural killer (NK) cells are important anti-tumor cells of our innate immune system. Their anti-cancer
activity is mediated through interaction of a wide array of activating and inhibitory receptors with their ligands on
tumor cells. After activation, NK cells also secrete a variety of pro-inflammatory molecules that contribute to the
final immune response by modulating other innate and adaptive immune cells. In this regard, external proteins
from NK cell secretome and the mechanisms by which they mediate these responses are poorly defined.
Methods: TRANS-stable-isotope labeling of amino acids in cell culture (TRANS-SILAC) combined with proteomic
was undertaken to identify early materials transferred between cord blood-derived NK cells (CB-NK) and multiple
myeloma (MM) cells. Further in vitro and in vivo studies with knock-down of histones and CD138, overexpression of
histones and addition of exogenous histones were undertaken to confirm TRANS-SILAC results and to determine
functional roles of this material transferred.
Results: We describe a novel mechanism by which histones are actively released by NK cells early after contact
with MM cells. We show that extracellular histones bind to the heparan sulfate proteoglycan CD138 on the surface
of MM cells to promote the creation of immune-tumor cell clusters bringing immune and MM cells into close
proximity, and thus facilitating not only NK but also T lymphocyte anti-MM activity.
Conclusion: This study demonstrates a novel immunoregulatory role of NK cells against MM cells mediated by
histones, and an additional role of NK cells modulating T lymphocytes activity that will open up new avenues to
design future immunotherapy clinical strategies.
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Introduction
Natural killer (NK) cells are important anti-tumor cells of
our innate immune system whose anti-tumor properties
led to anti-cancer, immune NK cell therapies under devel-
opment [1]. The majority of clinical studies infusing NK
cells worked mostly for acute myeloid leukemias but
performed poorly in other malignancies [2, 3], suggesting
that a deeper knowledge of NK cells is required to better
understand and exploit their anti-tumor activity. In this
regard, NK cells present a wide array of activating and
inhibitory receptors that interact with their ligands on
tumor cells [4]. However, besides these receptor-ligands
interactions, a cross-talk among different immune cells,
performed by pro-inflammatory molecules secreted by im-
mune cells, contributes to the final immune response [5].
The relevance of this cross-talk between immune cells
is observed after microbial infection, where dendritic
cells (DCs) activate NK cells through IL15 secretion
leading to T cell and monocyte activation [5–7]. The
coordination of these immune responses requires the
creation of cellular clusters to enable intercellular cross-
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: bmartina@clinic.cat
1Department of Hematology, Hospital Clinic, IDIBAPS, Carrer Rosselló
149-153, 08036 Barcelona, Spain
2Josep Carreras Leukaemia Research Institute, Carrer Rosselló 149-153, 08036
Barcelona, Spain
Full list of author information is available at the end of the article
Martín-Antonio et al. Journal for ImmunoTherapy of Cancer           (2019) 7:259 
https://doi.org/10.1186/s40425-019-0739-1













talk between immune cells [7, 8]. We previously
reported the relevance of this cell-cell contact as a
mechanism leading to a transmissible cytotoxicity from
cord blood derived NK cell (CB-NK) to neighboring
multiple myeloma (MM) cells, as CB-NK cytotoxicity is
transferred to ‘primary’ MM cells (1°MM) after contact;
and afterwards, it is passed from 1°MM to adjacent ‘sec-
ondary’ MM cells (2°MM) unexposed to CB-NK [9].
Interestingly, CB-NK perform Granzyme-B and Caspase-
3 independent killing of MM cells [9], suggesting the
involvement of other proteins in the CB-NK anti-MM
activity. Moreover, whereas effector cytokines require
hours to be detected, cell cluster formations occur earl-
ier, suggesting that other initiating molecules secreted at
early times of cell-cell contact will impact on the final
effector response.
These observations led us to hypothesize that novel
cytotoxic molecules transferred from CB-NK to MM
cells could be involved in the anti-MM CB-NK activity.
Therefore, TRANS-stable-isotope labeling of amino
acids in cell culture (TRANS-SILAC) [10] combined
with proteomic was undertaken to identify early mate-
rials transferred between CB-NK and MM. Analysis
revealed that histones are actively transferred between
CB-NK and MM and also released into the extracellular
milieu after co-culturing CB-NK and MM. Released CB-
NK histones bind to CD138 in MM cells promoting the
formation of CB-NK/MM cell clusters which facilitates
NK-MM contact and improves the anti-tumor NK
efficacy. Furthermore, NK-histones also promoted the
generation of cell clusters between T-cells and MM cells
increasing the T cell anti-MM activity and revealing a




NK cells were isolated from CB and PB by magnetic
depletion (Miltenyi Biotec). CB-NK expansion was
performed during 14 days as previously described [9]
using K562-based antigen presenting cells expressing
membrane bound IL-21 (“Clone 9.mbIL21”). T cells
were isolated from PB by magnetic depletion (Miltenyi
Biotec) and expanded during 5 days with Dynabeads®
Human T-Activator CD3/CD28 (Thermo-Fisher). IL2
(Proleukin) was added at 100UI/mL every other day.
Culture NK and T cell media was comprised of 45%
RPMI-1640 (Sigma-aldrich) and 45% Click’s (Irvine Sci-
entific) with 10% AB human serum (Atlanta Biologicals).
ARP1 cell line was provided by Multiple Myeloma
Research Center (Little Rock, AK). 293 T, K562, U266,
RPMI-8226, Ramos and Jurkat cells were obtained from
American Type Culture Collection (ATCC, Rockville,
MD). K562, ARP1, RPMI, Ramos and Jurkat were
cultured in RPMI-1640 with 10% fetal bovine serum
(FBS) and U266 with 15% FBS. 293 T cells were cultured
in DMEM with 10% FBS. CD138+ cells from MM
patients were obtained by MACS selection (Miltenyi
Biotec).
TRANS-SILAC proteomics
Was performed culturing cells in their usual media lack-
ing normal L-Arg, L-Leu and L-Lys, and supplemented
with their corresponding heavy isotopic AA (hAA).
ARP1-MM cells were expanded in this media for 21
days, and CB-NK during the 14 days of the usual CB-NK
in vitro expansion. After this period, both cell popula-
tions contained > 97% of hAA as determined by liquid
Chromatography-Tandem Mass Spectrometry (LC-MS/
MS). Percentage of heavy proteins transferred to each
cell population was analyzed by LC-MS/MS.
Cytotoxicity assays
Were performed at 3 h by Europium Release Assays [9],
and at longer times by flow cytometry calculating % of
remaining live GFP+ tumor cells applying the formula:
% of target cell lysis = 100-(% of GFP+ cells at 24-48 h /
% of GFP+ cells at 0 h).
In vivo myeloma murine model
NOD/SCID IL-2Rcnull (NSG) mice were irradiated and
inoculated i.v. with GFP-Firefly Luciferase-transduced
ARP1 cells. Recombinant H2AZ (0.5 mg/kg) was given
i.v. on day 1 and day 7. Disease progression was moni-
tored by bioluminescence using a Hamamatsu CDD
camera (Hamamatsu Photonics Sistems) following a 100
mL IP injection of D-luciferin (20 mg/mL), and measur-
ing serum kappa light chain levels by ELISA (Bethyl La-
boratories). Signal quantitation was performed with
ImageJ software.
Transfer of H2AZ-GFP transfer between cells
Cells were co-cultured staining in blue (CMAC) the cell
population of interest. Then, H2AZ-GFP transfer between
cells was analyzed by flow cytometry gating on the CMAC+
population and analyzing the % of CMAC+GFP+ cells.
Supernatant Containing Inflammatory Proteins (SIPs)
analysis
To analyze released proteins to the extracellular milieu
by each cell population, 30–40 min co-cultures experi-
ments were performed collecting the supernatants and
differentiating proteins of each cell population by their
previous hAA labeling (Additional file 1: Figure S1D).
Reagents
Caspase-1 inhibition was achieved with Y-VAD (50 μM)
addition. Heparinase III (Sigma-aldrich) treatment (0.01
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IU/mL) was used to remove HSGPG from MM cells
[11]. Recombinant H2AZ (Merck-Millipore) and H4
(New England Biolabs) were added in cell culture at
2 μM or 0.5 μM depending on the experiment. Heparin
(STEMCELL Technologies) was used at 20 IU/mL.
DNAse I (D2) (Worthington Biochemical Corporation)
was used at 100 IU/mL. Antibodies used were CD138-
V421 and CD56-V450 (BD Biosciences), H2AZ, H4,
H1.5, Anti-Rabbit IgG-HRP, and Anti-Rabbit IgG-Alexa
Fluor-647 (Cell Signaling Technology).
Cell cluster formation
Area of cell clusters was visualized at different time
points by measuring the GFP area from tumor cells
using ImageJ software.
Ethics Statement
Research involving human materials was approved by
Ethical Committee of Hospital Clinic, Barcelona. CB
units and PB were obtained from healthy donors who
gave informed consent.
Statistical analysis
Mann-Whitney U test was used to analyze comparison
between groups. Statistical analyses were performed with
SPSS (IBM SPSS v. 23).
LC-MS/MS, confocal fluorescence microscopy, flow
cytometry, GFP-fused protein generation, lentivirus
production and siRNA transfection are detailed in
Additional file 1: Supplementary Methods.
Results
CB-NK histones are dynamically transferred from CB-NK
to primary MM cells and subsequently to adjacent
secondary MM cells
In order to identify cytotoxic CB-NK proteins trans-
ferred directly to MM cells (1°MM), and secondarily to
neighboring MM cells (2°MM), TRANS-SILAC prote-
omic was performed to identify acquired proteome for
each cell population [10]. Co-culture experiments were
limited to 30–40 min to unravel early transferred pro-
teins between live cells responsible for initiating NK
cytotoxicity.
CB-NK were labeled with heavy amino acids (hAA) to
allow for identification of ‘heavy’ CB-NK proteome
transferred to 1°MM (labeled with CMAC); and subse-
quently from 1°MM to 2°MM (unstained) (Additional
file 1: Figure S1A). Proteomic data showed that after
CB-NK/1°MM co-culture, the 1°MM proteome
contained 9.5% of proteins transferred from CB-NK
(Fig. 1a) (Additional file 1: Table S1). Then, 1°MM were
co-cultured with fresh MM cells to determine CB-NK
proteins transferred secondarily between MM cells, re-
vealing 7.2% of secondary transfer of NK proteome from
the 1°MM to neighboring 2°MM cells. These proteins
were thus originally derived from CB-NK, but via 1°MM
(Fig. 1a, Additional file 1: Table S2). As a consequence of
this transfer, 1°MM lost part of their labeled, previously
acquired CB-NK proteome content that went down from
9.5 to 3.9% (Fig. 1a, Additional file 1: Table S3). These
data provided evidence for a primary-direct CB-NK prote-
ome transfer to 1°MM, and a secondary-indirect CB-NK
proteome transfer to 2°MM.
Analysis of CB-NK transferred proteins to MM cells
showed a high number of CB-NK histones acquired by
MM cells. In resting conditions, different histones were
present in CB-NK (Fig. 1b: CB-NK resting). However,
after co-culturing with 1°MM, CB-NK lost their histone
content (Fig. 1b: CB-NK after 1°MM), as indicated by
absence of detection of Peptide Spectral Matches
(PSMs). Conversely, MM cells underwent an enrichment
in these histones (Fig. 1b), suggesting the selectivity of
this process. We observed that subsequently, CB-NK
histones from 1°MM cells were then transferred to
2°MM cells (Fig. 1b: 2°MM), and as a consequence, the
content of labeled, CB-NK histones in 1°MM
disappeared (Fig. 1b: 1°MM after 2°MM), suggesting a
continuous, dynamic and specific transfer of CB-NK
histones between MM cells. Of note, other NK proteins
detected in the proteomic data (YWHAZ and YWHAQ)
did not show this pattern of continuous transfer
observed for histones (Fig. 1b).
MM cells exposed to CB-NK increase their intercellular
communication transferring proteins to CB-NK and to
neighboring MM cells
In a complementary approach, MM cells were expanded
in vitro with hAA to identify 1°MM proteome transferred
to CB-NK and to 2°MM (Additional file 1: Figure S1B). As
control, the transmission of MM proteome between MM
cells under ‘resting’ conditions (absence of CB-NK) was
also investigated (Additional file 1: Figure S1C). After CB-
NK exposure, CB-NK received 7.3% of MM proteome
(Fig. 1c, Additional file 1: Table S4). Moreover, whereas
under ‘resting’ conditions 2.5% of MM proteome was
transferred between MM cells (Fig. 1c, Additional file 1:
Table S5), after CB-NK, MM proteome transfer between
neighboring MM cells increased to 7.7% (Fig. 1c,
Additional file 1: Table S6). These experiments suggested
that MM cells display a low constitutive transfer of their
proteome, which is increased after CB-NK exposure lead-
ing to a bidirectional exchange of proteome.
CB-NK histones are also released into the extracellular
milieu after co-culture with MM cells
A third experiment co-culturing hAA-labeled MM cells
and CB-NK was performed to analyze released SIPs (Add-
itional file 1: Figure S1D). Proteomic analysis showed that
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SIPs contained 30% of CB-NK proteins and 70% of proteins
from hAA-labeled MM cells (Fig. 1d, Additional file 1:
Tables S7 and S8). Clustering analysis of this 30% of
CB-NK proteins by using STRING-database showed the
presence of histones in this released NK material. His-
tones are highly involved in inflammation and coagula-
tion mechanisms known as ‘immunothrombosis’ [12].
As shown in Fig. 1d, most of the other NK proteins de-
tected in the same cluster of histones (red cluster) are
also involved in inflammation, coagulation and/or cell
migration processes.
CB-NK histones are actively transferred through MM cells
Proteomic data suggested a dynamic movement of CB-
NK histones through different MM cells, as 1°MM lost
their CB-NK histones by passing them to 2°MM. As his-
tones show antimicrobial [13, 14] and anti-tumor prop-
erties [15], further studies were undertaken to confirm
their cell-cell transfer and impact on MM cells. Histone
variant H2AZ1 (H2AZ) was first selected due to the high
number of PSMs detected and to its presence in 1°MM
and 2°MM cells. In addition, YWHAZ and YWHAQ
were also selected for further analysis since these CB-
NK proteins were identified either in 1°MM or 2°MM
cells and are involved in tumor cell survival [16].
H2AZ, YWHAZ and YWHAQ fused to green fluores-
cent protein (GFP) were overexpressed in MM cells.
While YWHAZ-GFP and YWHAQ-GFP over-
expression had no effect on the in vitro proliferation of
ARP1 cells, H2AZ-GFP over-expression significantly de-
creased ARP1 proliferation (Fig. 2a), and this inhibitory
effect was not observed in CB-NK (Fig. 2a). Moreover,
when CB-NK were transduced with these GFP-fused
proteins and co-cultured with MM cells for 30 min,
transfer of these proteins from CB-NK to MM cells was
confirmed. While YWHAQ-GFP and YWHAZ-GFP
were transmitted from CB-NK to MM cells in vesicles
(Fig. 2b), H2AZ-GFP was transmitted by both vesicles
(Fig. 2c) and large intercellular structures co-localizing
with DNA (Additional file 1: Figure S2A). Moreover,
H2AZ-GFP also appeared to adhere to MM surface (Fig.
2c). In addition, H2AZ-intercellular structures were also
detected after co-culturing CB-NK with primary CD138+
cells from MM patients (Additional file 1: Figure S2B).
We next analyzed whether CB-NK could transfer H2AZ
to other cells besides MM cells. Co-culturing CB-NK-
H2AZ-GFP with MM and non-MM (K562) cell lines,
showed that a fraction of all tumor cell lines expressed
H2AZ-GFP after 24 h (Fig. 2d). To confirm that H2AZ
transfer was an active and regulated mechanism, the same
experiment was performed in parallel at 4 °C and 37 °C,
confirming an increased and active H2AZ transfer from
CB-NK to tumor cells at 37 °C, and that the degree of
transfer was lower for non-MM K562 (Fig. 2e).
Since H2AZ was transferred from CB-NK to MM cells
and then, secondarily between MM cells (Fig. 1b), we
next analyzed whether tumor (MM and non-MM K562)
cells over-expressing H2AZ could transfer this protein
to neighboring tumor cells in the absence of CB-NK. In-
deed, transmission of H2AZ-GFP to neighboring tumor
cells was observed in the absence of CB-NK (Fig. 2f).
The kinetics of H2AZ-GFP transfer between neighboring
MM cells was monitored from 1 to 18 h (Fig. 2g) dem-
onstrating that the rate of H2AZ transfer occurred at a
much lower rate than in the presence of CB-NK (Fig.
2e) and indicating that histone NK transfer to MM cells
is an active process. Different rates of H2AZ-GFP trans-
fer were observed for each cell line. Thus, although for
RPMI cells, the initial rate of H2AZ-GFP transfer was
relatively high, it increased less with extended time in
culture than for ARP1 and U266 cells where the initial
rate of H2AZ-GFP transfer was lower (Fig. 2g).
To investigate whether the transfer of materials be-
tween cells was unique to toxic proteins, or applic-
able to all proteins, we compared the transfer
kinetics of H2AZ-GFP and GFP. Although the actual
rates of transfer and proportion of protein trans-
ferred differed between the different cell lines, simi-
lar rates of transfer were observed for both
molecules (H2AZ-GFP and GFP) for each cell line
(Fig. 2h). Altogether, our results indicate that tumor
cells transfer proteins between them, and that the
presence of CB-NK cells greatly increases the trans-
fer rate.
(See figure on previous page.)
Fig. 1 Cord blood derived NK cells (CB-NK) increase cell-cell communication between CB-NK and MM cells, leading to enhanced proteome
transfer, including a high number of histones. a and c: Percentage of heavy-labeled (transferred) proteins from the total cell proteome in each
cell population after labeling either CB-NK (a) or MM cells (c) with heavy amino acids (hAA). Each cell population was obtained after co-culturing
and FACS sorting according to Diagram shown in Additional file 1: Figure S1. b: Schematic design of the cell populations analyzed which are
shown in the Table below to present trafficking of CB-NK histones and other NK proteins through MM cells (Additional file 1: Tables S1, S2 and
S3). Numbers in the table indicate number of PSMs (peptide spectral match) detected, indicating the relative abundance of proteins. Scheme
shows CB-NK in resting conditions and after co-culture with MM cells (1°MM). Afterwards, 1°MM cells transfer CB-NK histones secondarily to
neighboring MM cells (2°MM), with subsequent loss of CB-NK histones in 1°MM cells. d. Analysis of released proteins after CB-NK/MM cell co-
culture termed Supernatant containing Inflammatory Proteins (SIPs). See diagram shown in Additional file 1: Figure S1D. CB-NK proteins from SIPs
are shown in the diagram, and proteins of the red cluster, which includes histones (in a red circle), are detailed. See also Additional file 1: Tables
S1-S8 for list of transferred proteins
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Histones are involved in CB-NK anti-MM activity
To test whether H2AZ was involved in NK cytotoxicity,
we performed knock-down (siRNA) and over-expression
of H2AZ in CB-NK. H2AZ knock-down in CB-NK
reduced cytotoxicity against MM cells but not against
K562 cells (Fig. 3a), suggesting that although H2AZ is
transferred from CB-NK to K562 (Fig. 2d) it has no role
in the killing of K562. Conversely, H2AZ over-
expression in CB-NK increased their cytotoxicity against
MM cells in a different degree depending on the MM
cell line (Fig. 3b). No effect was detected for K562, con-
sistent with previous studies reporting that NK-
cytotoxicity against K562 is mainly mediated through
Granzyme B and Caspase-3 [9].
The role of H2AZ in the killing of MM cells by NK
was further confirmed by the assessment of peripheral
blood (PB)-NK. Although PB-NK expressed lower H2AZ
levels than CB-NK (Fig. 3c), H2AZ knock-down reduced
PB-NK cytotoxicity against MM cells, a finding not ob-
served against K562 (Fig. 3d), confirming also H2AZ in-
volvement in PB-NK anti-MM activity.
Finally, the impact of other histones (H4 and H1.5) in
CB-NK cytotoxicity was also assessed. Individual knock-
down of H2AZ, H4 and H1.5 in CB-NK (Additional file 1:
Figure S3) decreased CB-NK cytotoxicity against MM
cells, and not against K562 cells (Fig. 3e), confirming that,
as suggested in the proteomic data, histones are involved
in CB-NK anti-MM activity.
CB-NK and histones promote pyroptosis with in vivo MM
cell death and concomitant inflammation
Extracellular histones are highly pro-inflammatory and acti-
vate the inflammasome leading to pyroptosis, an inflamma-
tory form of cell death caspase-1-dependent [13, 17, 18].
Since NK cells show pro-inflammatory activity [19], and we
had previously discarded apoptosis as the form of cytotox-
icity [9], we hypothesized that CB-NK-associated histones
might induce pyroptosis to kill MM cells. Indeed, we found
that inhibition of Caspase-1 decreased CB-NK anti-MM ac-
tivity, an effect not detected in K562 cells (Fig. 4a).
Importantly, addition of recombinant H2AZ induced anti-
MM activity (Fig. 4b), a finding also observed for recombin-
ant H4 (Additional file 1: Figure S4). In these experimental
conditions, caspase-1 inhibition also reduced H2AZ-
mediated cytotoxicity (Fig. 4b).
To assess the anti-MM and inflammatory role for
histones in vivo, NSG-mice receiving ARP1 and treated
with recombinant H2AZ showed that administration of
H2AZ was associated with a remarkable delay in the
progression of MM (Fig. 4c-e). However, abnormally
enlarged lung and spleen tissues were observed, which
could result from inflammatory damage induced by
H2AZ (Fig. 4f). Interestingly, the phenotype of MM cells
in bone marrow and spleen from, H2AZ-treated mice
presented decreased intensity of CD138 (Fig. 4g), a
marker highly expressed on MM cells.
NK-histones specifically bind to CD138 on MM cell surface
We noticed that NK-histones adhered to MM cell
surface (Fig. 2c) and a decreased CD138 expression
in vivo in MM cells after H2AZ treatment (Fig. 4g).
In this regard, histones are cationic proteins that can
be neutralized with anionic proteins such as heparin
[20]. Interestingly, CD138 is a highly anionic type of
HSPG [21] greatly abundant in the surface of MM
cells, required for MM tumor growth, vascularization,
and metastasis, being essential for MM cells [22, 23].
Therefore, we hypothesized that cationic histones
would bind to anionic CD138 in tumor cells. After
confirming CD138 expression in MM cells (Fig. 5a),
MM cells were treated with either recombinant H2AZ
or H4 and stained for CD138 and CD56, two markers
of MM cells. Histone treatment decreased only
CD138 expression (Fig. 5b) suggesting that histones
were binding to CD138. Confocal fluorescence mi-
croscopy demonstrated a high colocalization of
CD138 and H2AZ (Fig. 5c and d). Moreover, co-
culture of CB-NK overexpressing H2AZ-GFP with
MM cells also demonstrated colocalization of CD138
and H2AZ (Fig. 5e).
(See figure on previous page.)
Fig. 2 CB-NK histones are actively transferred through MM cells. a: ARP1 and CB-NK cell proliferation during four days after over-expression of
YWHAQ-GFP, YWHAZ-GFP and H2AZ-GFP vs control, measured by viable cell count. b-c: Transfer of YWHAZ and YWHAQ (b), and H2AZ (c) from
CB-NK to ARP1 cells. CB-NK transduced with the corresponding protein fused to GFP are co-cultured with ARP1 cells for 30 min. ARP1 cells in
blue (CMAC) and CB-NK show in green the corresponding GFP-fused protein. Arrows in c indicate H2AZ-vesicles and H2AZ adhered to the
surface of MM cells. d: Transfer of H2AZ-GFP from CB-NK to MM (ARP1, RPMI and U266) and non-MM K562 cells after 24 h of co-culture. Target
cells are shown in blue (CMAC) in plot 1, and plot 2 corresponds to the gate of CMAC+ cells. e. Transfer of H2AZ-GFP from CB-NK to MM and
non-MM K562 cells after 24 h of co-culture performed in parallel at 37 °C and 4 °C. f to h: H2AZ can be transferred between tumor cells in a
CB-NK independent manner. f: Transfer of H2AZ from tumor cells over-expressing H2AZ-GFP to neighboring tumor cells stained in blue (CMAC)
after 30 min of co-culture. Arrows indicate H2AZ-vesicles and H2AZ-intercellular structure being transferred to neighboring tumor cells. g: H2AZ
transfer from MM cells over-expressing H2AZ-GFP to neighboring MM cells in blue (CMAC) at different times (1 h, 5 h, 18 h) of co-culture.
Statistical analysis shown is performed for each cell line vs 1 h time point. h: Transfer of GFP (plot on the left) and H2AZ-GFP (plot on the right)
from MM and non-MM K562 cells over-expressing these proteins to neighboring MM and non-MM K562 cells after 24 h of co-culture.
Representative images from at least three independent experiments
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In addition, MM cells were co-cultured with either CB-
NK control or CB-NK where histones (H2AZ, H4 and
H1.5) had been knocked-down (CB-NK siRNA Hist), and
CD138 expression was analyzed. Moreover, SIPs from
these co-cultures were taken and added into MM cells
alone to analyze also their impact in CD138 expression
(Fig. 5f). In both cases, CB-NK siRNA ctrl (Fig. 5g) and
SIPs siRNA ctrl (Fig. 5h) decreased CD138 expression in
MM cells, an effect which was reversed after knock-down
of histones (Fig. 5g and h). Additionally, SIPs did not
impact CD56 expression (Fig. 5h) further supporting the
specific binding of CB-NK histones to CD138.
Fig. 3 Histones are involved in CB-NK anti-MM activity. a. 3 h cytotoxicity assays comparing CB-NK control (CB-NK siRNA ctrl) vs CB-NK with
knockdown of H2AZ (CB-NK siRNA H2AZ). b. 3 h cytotoxicity assays comparing CB-NK control (CB-NK GFP) vs CB-NK over-expressing H2AZ (CB-NK
H2AZ). c. H2AZ levels in peripheral blood NK cells (PB-NK) vs CB-NK, analyzed by confocal fluorescence microscopy. Representative image of
H2AZ levels is shown on the right. d. 3 h cytotoxicity assays comparing PB-NK control (PB-NK siRNA ctrl) vs PB-NK with knockdown of H2AZ (PB-
NK siRNA H2AZ). e. 3 h cytotoxicity assays comparing CB-NK (CB-NK siRNA ctrl) with CB-NK where histones H2AZ, H4 and H1.5 were knockdown.
Assays were performed at least in three independent experiments. a: all groups analyzed compared to CB-NK siRNA ctrl are different (p < 0.05).
b: at least one group analyzed compared to CB-NK siRNA ctrl is different (p < 0.05). *p < 0.05. ** p < 0.001. Efficiency of knockdown of H2AZ was
confirmed by Western Blot and by flow cytometry (Additional file 1: Figure S3)
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NK-histones promote cell clustering formation required
for NK cell anti-MM activity
Proteomic data showed a high number of released NK
inflammatory proteins in the SIPs, including histones,
which were also involved in coagulation (Fig. 1d). The
innate immune system has the ability to initiate a
process termed ‘immunothrombosis’, whereby the re-
lease of inflammatory proteins, including histones, a
local intravascular scaffold is provided to immobilize,
contain and destroy pathogenic microorganisms [12, 24].
Interestingly, NK cells require high effector (E):target (T)
ratio for the NK and target cells to be in close proximity
for optimal anti-tumor efficacy. However, NK cells
represent 1–6% of peripheral blood leukocytes, therefore
a process that can promote a high localized E:T ratio
bringing NK and MM cells into close proximity would
be physiologically relevant. Therefore, we hypothesized
that histones were required for NK to promote cell clus-
tering thereby improving MM cell killing. It is known
that heparin inhibits immunothrombus formation, neu-
tralizes cationic histones [20] and also competes with
anionic HSPG for their binding to cationic ligands [11],
such as histones. Therefore, 24 h cytotoxicity assays with
heparin were performed at low E:T ratios, and the area
of cell clusters were measured at 2.5 h and at 24 h. Hep-
arin inhibited cell cluster formation (Additional file 1:
Fig. 4 CB-NK and histones promote pyroptosis with in vivo MM cell death and concomitant inflammation. a. 3 h cytotoxicity assays of CB-NK
against MM and non-MM K562 cells, adding Caspase-1 inhibitor to analyze the impact on pyroptotic cell death. b. Impact of recombinant H2AZ
on viability of MM and non-MM K562 cells. HSA: Human Serum Albumin (2 μM) was added as protein control in parallel with H2AZ (2 μM). Y-VAD
was added to analyze the impact on H2AZ effect. Cell proliferation was measured by viable cell count. c to g: Anti-MM and pro-inflammatory
in vivo activity of H2AZ. NSG mice received ARP1 cells and were treated with recombinant H2AZ. Weekly bioluminescence (c and d) images and
kappa ELISA light chains measurements (e) were performed. f. Lung and tissues of mice untreated (MM) or treated with H2AZ (MM + H2AZ).
g: CD138 expression in MM cells of mice tissues. *p < 0.05
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Figure S6A and Fig. 6a) and reduced the anti-MM CB-
NK activity (Fig. 6b), indicating that CB-NK requires
early cluster formation to perform anti-MM activity, as
it has been observed for NK antimicrobial activity [7].
For K562, the effect of heparin was minimal. The
absence of HLA-I expression by K562 cells makes these
cells strong targets for NK even in the absence of the
improved cell-cell contact provided by cell clustering.
Moreover, knock-down of histones in CB-NK also
decreased cell clusters formation at 4 h of co-culturing
Fig. 5 NK-histones specifically bind to CD138 on MM cell surface. a. CD138 expression in MM and non-MM K562 cells. b: MM cells incubated with
either H2AZ or H4 for 1 h and stained for CD138 and CD56. c-d: confocal microscopy images (c) and colocalization analysis (d) of CD138 and
H2AZ after addition of recombinant H2AZ to ARP1 MM cells. e. CB-NK overexpressing H2AZ-GFP co-cultured with MM cells showing co-
localization of H2AZ-GFP and CD138. f. MM cells and CB-NK (either ctrl or with knock-down of histones H2AZ, H4 and H1.5) were co-cultured for
3 h with MM cells and CD138 expression was analyzed (g). h. SIPs from co-cultures in f were added into MM cells alone for 40 min to analyze
CD138 and CD56 expression. *p < 0.05
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Fig. 6 (See legend on next page.)
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CB-NK and MM cells at low E:T ratios, an effect not ob-
served for K562 (Fig. 6c and d), confirming that CB-NK
histones are involved in the formation of these cell clus-
ters which are inhibited with heparin.
Furthermore, histones co-localize with DNA and were
found in the SIPs with other pro-inflammatory and pro-
coagulant proteins (Fig. 1d), some of which may origin-
ate from serum in the culture medium. Therefore, the
effects of both DNAse treatment and removal of serum
were tested. Removal of serum reduced cell clustering
formation (Fig. 6e) and CB-NK cytotoxicity against MM
(Fig. 6f). The serum impact was also observed for K562
(Fig. 6e and f), suggesting that the serum provides other
relevant proteins in addition to CB-NK histones. DNAse
treatment, on the other hand, did not impact CB-NK
cytotoxicity against MM or K562 cells (Fig. 6e and f)
suggesting a histone activity independent of DNA. Inter-
estingly, DNAse treatment increased cell clustering in
some cases (U266 in Fig. 6e).
In addition, same experiments were performed adding
recombinant H2AZ or H4 at a non-toxic dose neither
for CB-NK nor for target cells (Additional file 1: Figure
S5A-C). The addition of H2AZ or H4 increased the size
of cell clusters (Additional file 1: Figure S6B, Fig. 6g and
i) and the CB-NK anti-MM activity (Fig. 6h and j), being
this effect abrogated by the addition of heparin (Fig. 6g
to j). Consistently, heparin, H2AZ and H4 impact in the
CB-NK cytotoxicity against K562 was much lower or
non-detectable (Fig. 6g to j).
Last, to confirm interaction of CD138 and histones in
cell cluster formation and in CB-NK cytotoxicity, the ef-
fect of histones was evaluated in the absence of CD138
after Heparinase III treatment [11] or knock-down of
CD138 by siRNAs. Both heparinase III and siRNA treat-
ment reduced CD138 expression in MM cells (Fig. 6k
and l). Tumor cells (ARP1 and K562) after Heparinase
III treatment (ARP1HSPG- and K562HSPG-) and MM cells
after knock-down of CD138 (siRNA) were co-cultured
in parallel with CB-NK, adding exogenous recombinant
H2AZ and H4 at a non-toxic dose (Fig. 6m). Heparinase
III treatment and CD138 knock-down abolished the im-
pact of histones in cell cluster formation and in CB-NK
anti-MM activity (Fig. 6n and o) without changes in
cluster formation and cytotoxicity against K562 cells
(Additional file 1: Figure S6C).
Released NK-histones also promote T cell/MM cell
clustering increasing T cell anti-MM activity
As NK-histones were detected in the SIPs (Fig. 1d) and
given that NK cells can shape the antitumor activity of T
lymphocytes [25–28], we hypothesized that released NK-
histones would also increase T cell/MM cell cluster
formation facilitating anti-tumor T cell activity. There-
fore, SIPs obtained from CB-NK/MM co-cultures
(Fig. 7a) added into cytotoxicity assays of CD3 T lym-
phocytes against MM cells resulted in specifically
increased anti-MM T cell activity (Fig. 7b).
To further investigate whether histones contained in
the SIPs were responsible for the improved T-cell
killing of MM, H2AZ, H4 and H1.5 were knocked
down in CB-NK that were co-cultured with MM cells.
SIPs obtained from these co-cultures were added into
48 h cytotoxicity assays with T cells at low E:T ratios,
measuring area of cell clusters at 4 h (Fig. 7c).
Whereas SIPs from NK cells with siRNA control in-
creased the area of T cell/MM cell clusters (Fig. 7d
and e) as well as T cell anti-MM activity (Fig. 7f);
SIPs from NK with silenced histones showed dimin-
ished effects (Fig. 7d-f), confirming that histones
released from NK cells increase also T cell-MM cell
clustering and T cell anti-MM activity. For K562,
even though SIPs increased cell cluster formation be-
tween T cells and K562 cells, they could not increase
T cell cytotoxicity since K562 cells are not a target
for T cells.
We also tested whether recombinant H2AZ and H4
could also promote clustering of T cells with MM. In
both cases, the area of T cell/MM cell clusters (Fig. 7g, h
and j) and the anti-MM T-cell activity were increased
(Fig. 7i and k) in the presence of histones H2AZ and
H4. Heparin addition reversed the enhanced clustering
(Fig. 7g, h and j) and tumor cell killing (Fig. 7i and k).
Of note, heparin also reduced cluster formation between
T-cells and K562 cells, without changes in cytotoxicity.
(See figure on previous page.)
Fig. 6 NK histones promote cell clustering formation required for NK cells anti-MM activity. a: Cell clustering formation between CB-NK and MM-
GFP and non-MM K562-GFP cells at 2.5 h and 24 h analyzing in parallel the impact of heparin (Hep) (see also Additional file 1: Figure S6A). b: 24 h
cytotoxicity assays values obtained from co-cultures in a. c and d: Cell clustering formation at 2.5 h of co-culturing MM-GFP and non-MM K562-
GFP cells with either CB-NK ctrl (siRNA ctrl) or CB-NK with knock-down of histones (siRNA Hist). Bar size indicates 100 μm. e and f: Impact of
DNase and absence of Fetal bovine serum (FBS) in cell culture media on cell clustering formation (e) and CB-NK cytotoxicity (f) against MM and
non-MM K562 cells. Heparin was added in parallel as control. g-j: Impact of recombinant H2AZ (g and h) and H4 (i and j), in the formation of cell
clustering and in CB-NK cytotoxicity against MM and non-MM K562 cells. Cell clustering analysis was measured at 2.5 h (g and i) and cytotoxicity
at 24 h (h and j). See also Additional file 1: Figure S6B. k-o: CD138 impact on histones activity. k-l: CD138 expression in MM and K562 cells after
Heparinase III treatment for 1-2 h (k) and after CD138 knock-down with siRNAs (l). m. Tumor cells ctrl, after Heparinase III treatment (HSPG-) and
after CD138 knock-down (CD138−) were co-cultured with CB-NK adding exogenous H2AZ or H4 and cell clustering formation was evaluated at
2 h (n) and cytotoxicity at 6 h (o) (See also Additional file 1: Figure S6C). *p < 0.05. ** p < 0.001
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Fig. 7 Released NK cell histones also promote T cell/MM cell clustering increasing T cell anti-MM activity: a. CB-NK and MM cells were co-cultured
and the SIPs were collected and added into 3 h cytotoxicity assays against MM cells adding as effectors T cells (b). SIPs were added in parallel to
U266 cells alone as control, and CB-NK were also included as effectors to compare the efficacy. c-f: Impact of histones in the SIPs capacity to
increase T cell anti-tumor activity. CB-NK ctrl (siRNA ctrl) and CB-NK with knockdown of histones (siRNA Hist) were co-cultured with MM cells to
obtain both SIPs siRNA ctrl and SIPs siRNA Hist (c). These SIPs were added into T-cell/tumor cell co-cultures, and the impact on cell clustering
formation after 4 h (d-e) and on T cell cytotoxicity after 48 h was analyzed (f). g-k: Impact of recombinant H2AZ (g-i) and H4 (j and k), in the
formation of cell clustering after 4 h, and in the T cell cytotoxicity vs MM and non-MM K562 cells after 48 h. Heparin was added in parallel.
*p < 0.05. ** p < 0.001
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Histone impact is not a common mechanism for other
tumor types
Since NK-histones did not increase the anti-tumor activ-
ity of NK and T cells against K562 non-MM cells, we
aimed to assess whether this histone impact was specific
against MM. Thus, cytotoxicity assays of either NK or T
cells revealed a very low impact of exogenous H2AZ and
H4 in the NK and T cell anti-tumor activity against
lymphoid B cells (Ramos) (Additional file 1: Figure S6D
and E), and no impact was detected towards Jurkat T
cells (Additional file 1: Figure S6D and E) indicating a
specific histone activity against MM. Interestingly,
heparin reduced CB-NK and T cell cytotoxicity for both
Ramos and Jurkat cells (Additional file 1: Figure S6D
and E), suggesting that other proteins different to
histones and related to inflammation/immunothrombo-
sis could be involved in the anti-tumor activity against
Ramos and Jurkat cells. To support this hypothesis, ei-
ther Ramos or Jurkat T cells were co-cultured with CB-
NK to collect SIPs (Additional file 1: Figure S6F) that
were added in cytotoxicity assays with T cells and tumor
cells. As previously shown for MM, SIPs, containing a
high number of inflammatory proteins, increased both
cell cluster formation and T cell anti-tumor activity
against Ramos and Jurkat cells (Additional file 1: Figure
S6G and H). Taking together, our results demonstrate a
novel mechanism of histone-mediated NK cytotoxicity
through binding to CD138 on MM cell surface.
Discussion
The field of immunotherapy to treat cancer has grown
over recent years [29, 30]. While some strategies show
remarkable success [31, 32], others, including NK-based
therapies, have still yet to realize their full therapeutic
potential [1]. Access to banked CB has provided a source
of NK to expand NK cells to clinically-relevant doses
making NK-based cellular immunotherapies a real possi-
bility [33–35]. The mechanisms by which NK kill tumor
cells are becoming better understood. Previous evidence
showing the relevance of NK-tumor cell communication
events in mechanisms leading to a transmissible anti-
tumor activity [9], suggested us to perform TRANS-
SILAC proteomics to unravel novel transmitted cyto-
toxic NK molecules. Surprisingly, we identified a high
number of CB-NK histones actively and early transferred
to MM and participating in the killing of MM cells. NK-
histones, through binding to CD138 on MM cells,
promoted the formation of immune-tumor cell clusters,
facilitating the immune attack of not only NK cells but
also T lymphocytes.
Here, TRANS-SILAC proteomic analysis and further
assays showed that histones were dynamically trans-
ferred from CB-NK through different MM cells, and also
released to the extracellular milieu. Histones release is a
phenomenon performed by neutrophils in Neutrophil
Extracelullar Traps (NETs) which consist of fibril matrix
containing histones to immobilize and eliminate micro-
bial pathogens [36, 37]. We confirmed that NK cells also
release histones in vesicles and in similar structures to
NETs, and that in addition to their well-known anti-
microbial activity [36, 37], H2AZ and H4 per se exerted
a growth inhibitory effect in MM cells in vitro and also
in vivo for H2AZ, being in agreement with previously
described anti-tumor properties of histones [15, 38]. In
addition to this growth inhibitory effect, we found that
histones are involved in CB-NK anti-MM activity as part
of the cytotoxic arsenal of NK cells to perform anti-MM
activity.
The existence of an immunoregulatory NK cell sub-
population [39] suggests a relevant role for this NK pro-
inflammatory activity [19]. In this regard, NK cells re-
lease pro-inflammatory granulysin and granzymes,
whose role is not completely understood [40], and
cytokines which coordinate the immune response by
recruiting DCs [25–28] and promoting T-cell activity
[41]. However, effector cytokines secreted by NK cells
are detected after 2–3 h of immune cell-tumor cell con-
tact, suggesting the existence of other molecules released
earlier and responsible for initiating these processes.
Here, we provide evidence of the pro-inflammatory
nature of NK histones [18, 36] by activating pyroptosis
[13, 18, 42] in MM. Histones in collaboration with other
pro-inflammatory molecules form the first line of
defense to eliminate pathogens by initiating immuno-
thrombosis, a complex process where neutrophil
histones contribute to generate an intravascular scaffold
for containment, exposure and destruction of pathogens
[12, 24]. This process, illustrating the relevance of multi-
cellular clusters to enable cross-talk between immune
cells to eliminate microbial pathogens [7, 8], appears
analogous to the capacity of histones to create both NK/
tumor and T-cell/tumor clusters to improve NK and T
cell anti-MM activity. This additional immunoregulatory
ability of NK cells should be considered in immunother-
apy strategies, especially given the fact that NK cells
constitute 1–6% of leukocytes in PB. Importantly, DCs
promote clustering and NK cell activation after bacterial
infection [7] leading to T cell activation, a process which
is detected after a few hours [7]. Here, we demonstrate
that histones secreted by NK cells at early time points
contribute to this effect in the absence of DCs, suggest-
ing a role for other proteins as initiators of the whole ef-
fector immune response.
In addition, our proteomic approach provided with a
method to detect NK proteins with anti-MM activity,
suggesting the use of this technique to detect specific
anti-tumor proteins. The observed anti-MM activity of
NK-histones was proposed to be mediated through
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binding to CD138, a HSPG present on the surface of
MM cells [43]. HSPGs are composed of proteins bound
to polyanionic heparan sulfate chains that provide add-
itional negative charges to the already anionic nature of
lipid membranes [44]. These negative charges enable
HSPG-mediated endocytosis of macromolecules. Specif-
ically, HSPG can uptake arginine and lysine rich
peptides [45, 46], which interestingly are highly enriched
in histones [47], and could explain the observed histone
affinity for CD138. The disappearance of histone impact
after CD138 knock-down, and after heparin treatment, a
competitor of HSPG for their binding to cationic ligands
[11], and the co-localization of histones with CD138
confirmed that histone activity requires binding to
CD138 on MM cells. Even though we only analyzed the
effect of histones over CD138, NK histones might bind
to other types of HSPG and should require further
investigation.
In conclusion, this study demonstrates by first time a
new anti-MM mechanism of CB-NK mediated by early
histone-transfer and release, where histones bind to
CD138 promoting immune-tumor cell clustering facili-
tating both NK and T cell anti-tumor activity. Consider-
ing the poor clinical results infusing NK cells, this
additional role of NK cells modulating T lymphocytes
could open up new avenues for future immunotherapy
studies.
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